[1] ZWIERS C,VAN KAMP I,OEPKES D,et al.Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn- review on current management and outcome[J].Expert Rev Hematol,2017,10(4):337-344.
[2] OLUSANYA B O,OSIBANJO F B,SLUSHER T M.Risk factors for severe neonatal hyperbilirubinemia in low and middle-income countries:a systematic review and meta-analysis[J].PLoS One,2015,10(2):e0117229.
[3] KRISTINSDOTTIR T,KJARTANSSON S,HARDARDOTTIR H,et al.Positive Coomb's test in newborns; causes and clinical consequences summary of cases diagnosed in the blood bank in the years 2005 to 2012[J].Laeknabladid,2016,102(7-8):326-331.
[4] SENTERRE T,MINON J M,RIGO J.Neonatal ABO incompatibility underlies a potentially severe hemolytic disease of the newborn and requires adequate care[J].Arch Pediatr,2011,18(3):279-282.
[5] 邵肖梅,叶鸿瑁,邱小汕.实用新生儿学[M].4版.北京:人民卫生出版社,2012:300-302.
[6] ALKAN OZDEMIR S,OZER E A,KOSE S,et al.Reference values of serum IgG and IgM levels in preterm and term newborns[J].J Matern Fetal Neonatal Med,2016,29(6):972-976.
[7] MARTINÓN-TORRES F,CZAJKA H,CENTER K J,et al.13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants[J].Pediatrics,2015,135(4):876-886.
[8] XU Y,MAHMOOD I,ZHONG L,et al.Passive immunoprophylaxis for the protection of the mother and her baby:insights from in vivo models of antibody transport[J].J Immunol Res,2017,2017:1-8.
[9] LI L,HUANG L,LUO G,et al.Prenatal treatment of severe fetal hemolytic disease due to anti-M alloimmunization by serial intrauterine transfusions[J].Taiwan J Obstet Gynecol,2017,56(3):379-381.
[10] MAAYAN-METZGER A,LEIBOVITCH L,SCHUSHAN-EISEN I,et al.Maternal anti-D prophylaxis during pregnancy and risk of hemolysis among preterm infants[J].J Perinatol,2014,34(12):906-908.
[11] BHUTANI V K,WONG R J.Risk profiles for haemolytic and nonhaemolytic neonatal jaundice[J].Acta Paediatr,2016,105(12):1387-1388.
[12] BHUTANI V K,SRINIVAS S,CASTILLO CUADRADO M E,et al.Identification of neonatal haemolysis:an approach to predischarge management of neonatal hyperbilirubinemia[J].Acta Paediatr,2016,105(5):e189-194.
[13] BARCELLINI W.Immune hemolysis:diagnosis and treatment recommendations[J].Semin Hematol,2015,52(4):304-312.
[14] YOGEV-LIFSHITZ M,LEIBOVITCH L,SCHUSHAN-EISEN I,et al.Indication of mild hemolytic reaction among preterm infants with ABO incompatibility[J].Pediatr Blood Cancer,2016,63(6):1050-1053.
[15] SGRO M,KANDASAMY S,SHAH V,et al.Severe neonatal hyperbilirubinemia decreased after the 2007 Canadian guidelines[J].J Pediatr,2016,171:43-47. |